Traws Pharma (TRAW) Operating Income (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Operating Income of -$6.9 million for Q1 2026, down 33.5% year-over-year from -$10.4 million in Q1 2025, and up 5.73% quarter-over-quarter from -$7.4 million in Q4 2025.
Traws Pharma (TRAW) Operating Income (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Operating Income for 15 consecutive years, with -$6.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 33.5% year-over-year to -$6.9 million; the TTM figure through Mar 2026 stood at -$19.6 million (up 86.22% YoY), while the FY2025 annual figure was -$17.9 million, up 87.45% from the prior year.
- Operating Income climbed to -$6.9 million in Q1 2026 per TRAW's latest filing, from -$7.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$1.2 million in Q2 2025 and bottomed at -$123.3 million in Q2 2024.
- Historically, Operating Income has averaged -$12.2 million across 5 years, with a median of -$5.2 million in 2024.
- Annual changes were most pronounced in 2024 — Operating Income plunged 2575.66% — and 2025, when it jumped 98.99%.
- Traws Pharma's Operating Income stood at -$5.7 million in 2022, then increased by 22.18% to -$4.5 million in 2023, then decreased by 18.29% to -$5.3 million in 2024, then slumped by 39.6% to -$7.4 million in 2025, then climbed by 5.73% to -$6.9 million in 2026.
- Business Quant data shows TRAW's Operating Income at -$6.9 million in Q1 2026, -$7.4 million in Q4 2025, and -$4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Traws Pharma | 5.54 Mn | 527,765.92 | - | -3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.95 Mn |
| Dec 31, 2025 | -7.37 Mn |
| Sep 30, 2025 | -4.06 Mn |
| Jun 30, 2025 | -1.25 Mn |
| Mar 31, 2025 | -5.20 Mn |
| Dec 31, 2024 | -5.28 Mn |
| Sep 30, 2024 | -8.54 Mn |
| Jun 30, 2024 | -123.35 Mn |
| Mar 31, 2024 | -5.21 Mn |
| Dec 31, 2023 | -4.46 Mn |
| Sep 30, 2023 | -5.09 Mn |
| Jun 30, 2023 | -4.61 Mn |
| Mar 31, 2023 | -6.14 Mn |
| Dec 31, 2022 | -5.73 Mn |
| Sep 30, 2022 | -5.64 Mn |
| Jun 30, 2022 | -4.12 Mn |
| Mar 31, 2022 | -4.13 Mn |
| Dec 31, 2021 | -3.76 Mn |
| Sep 30, 2021 | -3.99 Mn |
| Jun 30, 2021 | -4.65 Mn |